切换至 "中华医学电子期刊资源库"
高级检索
中华普通外科学文献(电子版)

中华普通外科学文献(电子版) ›› 2019, Vol. 13 ›› Issue (06) : 488 -491. doi: 10.3877/cma.j.issn.1674-0793.2019.06.016

所属专题： 专题评论； 文献；

综述

终末期肝病模型及MELD-Na评分在肝移植应用中的研究进展
陈永泰1, 柯瑞盛2, 蔡秋程3, 吕立志3, 陈永标3, 江艺3,†()   
  1. 1. 350025　福州，福建医科大学福总临床医学院
    2. 361001　厦门大学第一附属医院普外科
    3. 350025　福州，中国人民解放军联勤保障部队第九〇〇医院肝胆外科
  • 收稿日期:2019-02-21 出版日期:2019-12-01
  • 通信作者: 江艺
  • 基金资助:
    全军后勤医学研究重大项目(CNJ15J002、14ZX22); 福建省自然科学基金面上项目(2016J01585、2018J01351); 福建医科大学科研启航课题基金项目(2017XQ2048)

Advances in the application of model for end-stage liver disease and MELD-Na scores in liver transplantation

Yongtai Chen1, Ruisheng Ke2, Qiucheng Cai3, Lizhi Lyu3, Yongbiao Chen3, Yi Jiang3,†()   

  1. 1. Fuzong Clinical Medical College of Fujian Medical University, Fuzhou 350025, China
    2. Department ofGeneral Surgery, the First Affiliated Hospital of Xiamen University, Xiamen 361001, China
    3. Department of Hepatobiliary Surgery, the 900th Hospital of the Joint Logistics Team, Fuzhou 350025, China
  • Received:2019-02-21 Published:2019-12-01
  • Corresponding author: Yi Jiang
  • About author:
    Corresponding author: Jiang Yi, Email:
全文 ( ) 下载PDF ( ) 导出引用
引用本文：

陈永泰, 柯瑞盛, 蔡秋程, 吕立志, 陈永标, 江艺. 终末期肝病模型及MELD-Na评分在肝移植应用中的研究进展[J]. 中华普通外科学文献(电子版), 2019, 13(06): 488-491.

Yongtai Chen, Ruisheng Ke, Qiucheng Cai, Lizhi Lyu, Yongbiao Chen, Yi Jiang. Advances in the application of model for end-stage liver disease and MELD-Na scores in liver transplantation[J]. Chinese Archives of General Surgery(Electronic Edition), 2019, 13(06): 488-491.

终末期肝病模型（MELD）被认为能较好地评价终末期肝病患者的疾病状态，并且已应用于肝移植的器官分配。本文简要介绍了MELD和MELD-Na评分与等待肝移植患者的死亡率，以及肝移植患者术中输血、术后生存和并发症、再移植的关系。

关键词: 终末期肝病, 肝移植, MELD-Na评分, 术后并发症

The model for end-stage liver disease (MELD) is considered to be a good predictor of disease status in patients with end-stage liver disease and has been used for organ distribution in liver transplantation. This article briefly describes the relationship between MELD, MELD-Na score and the mortality of patients waiting for liver transplantation, the intraoperative blood transfusion, the survival, complications, and re-transplantation after liver transplantation.

Key words: End stage liver disease, Liver transplantation, MELD-Na score, Postoperative complications
[1]
Kamath PS, Wiesner RH, Malinchoc M, et al. A model to predict survival in patients with end-stage liver disease[J]. Hepatology, 2001, 33(2): 464-470.
[2]
Umemura T, Shibata S, Sekiguchi T, et al. Serum sodium concentration is associated with increased risk of mortality in patients with compensated liver cirrhosis[J]. Hepatol Res, 2015, 45(7): 739-744.
[3]
Biggins SW, Kim WR, Terrault NA, et al. Evidence-based incorporation of serum sodium concentration into MELD[J]. Gastroenterology, 2006, 130(6): 1652-1660.
[4]
Zhang Q, Guo X, Zhao S, et al. Prognostic performance of clinical indices and model scorings for acute-on-chronic liver failure: A study of 164 patients[J]. Exp Ther Med, 2016, 11(4): 1348-1354.
[5]
Burak KW, Meeberg GA, Myers RP, et al. Validation, current use and future directions of the model for end-stage liver disease for liver transplant allocation in Canada[J]. Can J Gastroenterol Hepatol, 2015: 16942.
[6]
Kalra A, Wedd JP, Biggins SW. Changing prioritization for transplantation: MELD-Na, hepatocellular carcinoma exceptions, and more[J]. Curr Opin Organ Transplant, 2016, 21(2): 120-126.
[7]
Fayad L, Narciso-Schiavon JL, Lazzarotto C, et al. The performance of prognostic models as predictors of mortality in patients with acute decompensation of cirrhosis[J]. Ann Hepatol, 2015, 14(1): 83-92.
[8]
Peng Y, Qi X, Tang S, et al. Child-Pugh, MELD, and ALBI scores for predicting the in-hospital mortality in cirrhotic patients with acute-on-chronic liver failure[J]. Expert Rev Gastroenterol Hepatol, 2016, 10(8): 971-980.
[9]
McPhail MJ, Farne H, Senvar N, et al. Ability of King’s College criteria and model for end-stage liver disease scores to predict mortality of patients with acute liver failure: A Meta-analysis[J]. Clin Gastroenterol Hepatol, 2016, 14(4): 516-525，e515.
[10]
Lai YH, Duan WD, Yu Q, et al. Outcomes of liver transplantation for end-stage biliary disease: A comparative study with end-stage liver disease[J]. World J Gastroenterol, 2015, 21(20): 6296-6303.
[11]
Annamalai A, Harada MY, Chen M, et al. Predictors of mortality in the critically ill cirrhotic patient: Is the model for end-stage liver disease enough?[J]. J Am Coll Surg, 2017, 224(3): 276-282.
[12]
Nagai S, Chau LC, Schilke RE, et al. Effects of allocating livers for transplantation based on model for end-stage liver disease-sodium scores on patient outcomes[J]. Gastroenterology, 2018, 155(5): 1451-1462，e1453.
[13]
Boin IF, Leonardi MI, Luzo AC, et al. Intraoperative massive transfusion decreases survival after liver transplantation[J]. Transplant Proc, 2008, 40(3): 789-791.
[14]
Makroo RN, Walia RS, Aneja S, et al. Preoperative predictors of blood component transfusion in living donor liver transplantation[J]. Asian J Transfus Sci, 2013, 7(2): 140-146.
[15]
Massicotte L, Beaulieu D, Roy JD, et al. MELD score and blood product requirements during liver transplantation: no link[J]. Transplantation, 2009, 87(11): 1689-1694.
[16]
Jacob M, Copley LP, Lewsey JD, et al. Pretransplant MELD score and post liver transplantation survival in the UK and Ireland[J]. Liver Transpl, 2004, 10(7): 903-907.
[17]
Sharma P, Schaubel DE, Goodrich NP, et al. Serum sodium and survival benefit of liver transplantation[J]. Liver Transpl, 2015, 21(3): 308-313.
[18]
Klein KB, Stafinski TD, Menon D. Predicting survival after liver transplantation based on pre-transplant MELD score: A systematic review of the literature[J]. PLoS One, 2013, 8(12): e80661.
[19]
余忠山, 江艺, 蔡秋程, 等. MELD评分和CTP分级评估肝移植术后并发症及死亡风险的临床分析[J/CD]. 中华普通外科学文献（电子版）, 2013, 7(6): 466-471.
[20]
Zhang QK, Wang ML. Value of model for end-stage liver disease-serum sodium scores in predicting complication severity grades after liver transplantation for acute-on-chronic liver failure[J]. Transplant Proc, 2019, 51(3): 833-841.
[21]
Lim S, Kim EJ, Lee TB, et al. Predictors of postoperative infectious complications in liver transplant recipients: experience of 185 consecutive cases[J]. Korean J Intern Med, 2018, 33(4): 798-806.
[22]
Foxton MR, Al-Freah MA, Portal AJ, et al. Increased model for end-stage liver disease score at the time of liver transplant results in prolonged hospitalization and overall intensive care unit costs[J]. Liver Transpl, 2010, 16(5): 668-677.
[23]
González Martínez S, Molina Raya A, Becerra Massare A, et al. Liver transplantation in recipients with high model for end-stage liver disease score[J]. Transplant Proc, 2018, 50(2): 595-597.
[24]
Smith JO, Shiffman ML, Behnke M, et al. Incidence of prolonged length of stay after orthotopic liver transplantation and its influence on outcomes[J]. Liver Transpl, 2009, 15(3): 273-279.
[25]
Schlegel A, Linecker M, Kron P, et al. Risk assessment in high- and low-MELD liver transplantation[J]. Am J Transplant, 2017, 17(4): 1050-1063.
[26]
Wronka KM, Grat M, Stypułkowski J, et al. Liver transplantation outcomes in recipients with high model for end-stage liver disease (MELD) scores: The relevance of MELD scores[J]. Ann Transplant，2017, 22: 251-256.
[27]
Cheng Y, Wei GQ, Cai QC, et al. Prognostic value of model for end-stage liver disease incorporating with serum sodium score for development of acute kidney injury after liver transplantation[J]. Chin Med J (Engl), 2018, 131(11): 1314-1320.
[28]
刘东岳, 解曼, 孔心涓, 等. 实体器官移植受者移植术后下消化道并发症流行病学及影响因素[J/CD]. 中华移植杂志(电子版), 2019, 13(1): 71-74.
[29]
Seehofer D, Eurich D, Veltzke-Schlieker W, et al. Biliary complications after liver transplantation: old problems and new challenges[J]. Am J Transplant, 2013, 13(2): 253-265.
[30]
Berumen J, Hemming A. Liver retransplantation: How much is too much?[J]. Clin Liver Dis, 2017, 21(2): 435-447.
[31]
Rana A, Petrowsky H, Kaplan B, et al. Early liver retransplantation in adults[J]. Transpl Int, 2014, 27(2): 141-151.
[32]
Kim HJ, Larson JJ, Lim YS, et al. Impact of MELD on waitlist outcome of retransplant candidates[J]. Am J Transplant, 2010, 10(12): 2652-2657.
[33]
Shah JA, Patel MS, Kratz JR, et al. High risk, high reward: An analysis of outcomes for candidates awaiting hepatic re-transplantation[J]. Ann Hepatol, 2016, 15(6): 888-894.
[34]
Hong JC, Kaldas FM, Kositamongkol P, et al. Predictive index for long-term survival after retransplantation of the liver in adult recipients: Analysis of a 26-year experience in a single center[J]. Ann Surg, 2011, 254(3): 444-448.
[35]
Biggins SW, Gralla J, Dodge JL, et al. Survival benefit of repeat liver transplantation in the United States: A serial MELD analysis by hepatitis C status and donor risk index[J]. Am J Transplant, 2014, 14(11): 2588-2594.
[36]
Al-Saeedi M, Yassein T, Schultze D, et al. Impact of inter-laboratory variability on model of end-stage liver disease (MELD) score calculation[J]. Ann Hepatol, 2016, 15(21): 675-682.
[37]
Myers RP, Shaheen AA, Aspinall AI, et al. Gender, renal function, and outcomes on the liver transplant waiting list: assessment of revised MELD including estimated glomerular filtration rate[J]. J Hepatol, 2011, 54(3): 462-470.
[1] 夏效泳, 王立超, 朱治国, 丛云海, 史宗新. 深度塌陷性胫骨平台骨折的形态特点和治疗策略[J]. 中华关节外科杂志(电子版), 2023, 17(05): 625-632.
[2] 杜滨和, 徐楠, 杨云川, 崔培元. 5项改良衰弱指数预测胰十二指肠切除术近期预后的价值探讨[J]. 中华普通外科学文献(电子版), 2023, 17(06): 444-448.
[3] 李坤河, 寇萌佳, 邝立挺. 肝移植术后二次气管插管的危险因素及预测模型的建立[J]. 中华普通外科学文献(电子版), 2023, 17(05): 366-371.
[4] 李建美, 邓静娟, 杨倩. 两种术式联合治疗肝癌合并肝硬化门静脉高压的安全性及随访评价[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 41-44.
[5] 逄世江, 黄艳艳, 朱冠烈. 改良π形吻合在腹腔镜全胃切除消化道重建中的安全性和有效性研究[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 66-69.
[6] 杨体飞, 杨传虎, 陆振如. 改良无充气经腋窝入路全腔镜下甲状腺手术对喉返神经功能的影响研究[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 74-77.
[7] 陈垚, 徐伯群, 高志慧. 改良式中间上入路根治术治疗甲状腺癌的有效性安全性研究[J]. 中华普外科手术学杂志(电子版), 2023, 17(06): 619-622.
[8] 陈大敏, 曹晓刚, 曹能琦. 肥胖对胃癌患者手术治疗效果的影响研究[J]. 中华普外科手术学杂志(电子版), 2023, 17(06): 651-653.
[9] 潘冰, 吕少诚, 赵昕, 李立新, 郎韧, 贺强. 淋巴结清扫数目对远端胆管癌胰十二指肠切除手术疗效的影响[J]. 中华肝脏外科手术学电子杂志, 2023, 12(06): 608-612.
[10] 严庆, 刘颖, 邓斐文, 陈焕伟. 微血管侵犯对肝癌肝移植患者生存预后的影响[J]. 中华肝脏外科手术学电子杂志, 2023, 12(06): 624-629.
[11] 廖梅, 张红君, 金洁玚, 吕艳, 任杰. 床旁超声造影对肝移植术后早期肝动脉血栓的诊断价值[J]. 中华肝脏外科手术学电子杂志, 2023, 12(06): 630-634.
[12] 李秉林, 吕少诚, 潘飞, 姜涛, 樊华, 寇建涛, 贺强, 郎韧. 供肝灌注液病原菌与肝移植术后早期感染的相关性分析[J]. 中华肝脏外科手术学电子杂志, 2023, 12(06): 656-660.
[13] 吕垒, 冯啸, 何凯明, 曾凯宁, 杨卿, 吕海金, 易慧敏, 易述红, 杨扬, 傅斌生. 改良金氏评分在儿童肝豆状核变性急性肝衰竭肝移植手术时机评估中价值并文献复习[J]. 中华肝脏外科手术学电子杂志, 2023, 12(06): 661-668.
[14] 崔佳琪, 吴迪, 陈海艳, 周惠敏, 顾元龙, 周光文, 杨军. TACE术后并发肝脓肿的临床诊治分析[J]. 中华肝脏外科手术学电子杂志, 2023, 12(06): 688-693.
[15] 王孟龙. 肿瘤生物学特征在肝癌肝移植治疗中的意义[J]. 中华肝脏外科手术学电子杂志, 2023, 12(05): 490-494.
阅读次数
全文


摘要

版权所有 中华医学会 中华医学电子音像出版社有限责任公司  京ICP备14006079号-1  网络出版服务许可证：(署)网出证(京)字第075号